BPG is committed to discovery and dissemination of knowledge
Editorial
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Diabetes. Aug 15, 2026; 17(8): 115342
Published online Aug 15, 2026. doi: 10.4239/wjd.115342
RRM2 and the ferroptosis-oxidative stress axis in diabetic kidney disease: Emerging insights from recent evidence
Tong-Jian Zhao, Nian-Zhe Sun
Tong-Jian Zhao, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02115, United States
Nian-Zhe Sun, National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Nian-Zhe Sun, Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Author contributions: Zhao TJ wrote the first draft, developed the main ideas, and led revisions; Sun NZ provided critical feedback, improved the structure, and added key examples.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Nian-Zhe Sun, MD, National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha 410008, Hunan Province, China. sunnzh201921@sina.com
Received: October 15, 2025
Revised: December 11, 2025
Accepted: December 29, 2025
Published online: August 15, 2026
Processing time: 295 Days and 2.4 Hours
Core Tip

Core Tip: Recent evidence identifies RRM2 as a regulator of ferroptosis in diabetic kidney disease (DKD) through activation of the PI3K/Akt/Nrf2 pathway. This editorial highlights the significance of this finding, critically evaluates its limitations, and discusses its potential as a biomarker and therapeutic target in DKD.

Write to the Help Desk